|
|
|
|
|
|
|
||
© The Rockefeller University Press,
0021-9525/2001//753 $5.00
The Journal of Cell Biology, Volume 152, Number 4,
, 2001 753-764
Original Article |
Activation of Nuclear Factor 
b and bcl-x Survival Gene Expression by Nerve Growth Factor Requires Tyrosine Phosphorylation of IB
prehn{at}uni-muenster.de
NGF has been shown to support neuron survival by activating the transcription factor nuclear factor-
B (NFB). We investigated the effect of NGF on the expression of Bcl-xL, an anti–apoptotic Bcl-2 family protein. Treatment of rat pheochromocytoma PC12 cells, human neuroblastoma SH-SY5Y cells, or primary rat hippocampal neurons with NGF (0.1–10 ng/ml) increased the expression of bcl-xL mRNA and protein. Reporter gene analysis revealed a significant increase in NFB activity after treatment with NGF that was associated with increased nuclear translocation of the active NFB p65 subunit. NGF-induced NFB activity and Bcl-xL expression were inhibited in cells overexpressing the NFB inhibitor, IB
. Unlike tumor necrosis factor- (TNF-), however, NGF-induced NFB activation occurred without significant degradation of IBs determined by Western blot analysis and time-lapse imaging of neurons expressing green fluorescent protein–tagged IB. Moreover, in contrast to TNF-, NGF failed to phosphorylate IB at serine residue 32, but instead caused significant tyrosine phosphorylation. Overexpression of a Y42F mutant of IB potently suppressed NFG-, but not TNF-–induced NFB activation. Conversely, overexpression of a dominant negative mutant of TNF receptor-associated factor-6 blocked TNF-–, but not NGF-induced NFB activation. We conclude that NGF and TNF- induce different signaling pathways in neurons to activate NFB and bcl-x gene expression.
Key Words: nerve growth factor • nuclear factor-B • Bcl-xL • tumor necrosis factor- • IB
© 2001 The Rockefeller University Press
 |
Introduction |
|---|
 TopAbstract Introduction Materials and MethodsResultsDiscussionReferences |
|---|
Little is known about the regulation of bcl-x gene expression in the nervous system. In blood cells, transcription of the bcl-x gene is controlled by transcription factors, signal transducer, and activator of transcription 5 and nuclear factor B (NFB) (Dumon et al. 1999; Lee et al. 1999; Socolovsky et al. 1999; Chen et al. 2000). Binding sites for the active NFB subunits p65/relA and c-rel have been demonstrated by functional analysis of the bcl-x promoter (Chen et al. 1999; Lee et al. 1999). Cytokines such as tumor necrosis factor (TNF)- activate NFB by inducing the degradation of IB proteins. These are cytosolic proteins associated with NFB subunits that function as their inhibitors (Baeuerle and Baltimore 1988). Degradation of IB proteins has been shown to involve phosphorylation at serine residues, ubiquitination, and subsequent degradation via the 26S proteasome complex (Palombella et al. 1994; Brown et al. 1995; Traenckner et al. 1995).
We have previously shown that the cytokine transforming growth factor-β1 also regulates the expression of the anti–apoptotic proteins Bcl-xL and Bcl-2 in primary neuron cultures (Prehn et al. 1994, Prehn et al. 1996). Likewise, the pro-inflammatory cytokine TNF- has recently been shown to increase Bcl-xL expression in neurons in an NFB-dependent manner (Tamatani et al. 1999). However, there is growing evidence that NFB activation is not only involved in the nervous system response to injury or inflammation, but is also required to support neuron survival during development and in the adult nervous system. Activation of excitatory amino acid receptors (Kaltschmidt et al. 1995) and release of neurotrophic factors may mediate constitutive NFB activity in neurons (Carter et al. 1996; Maggirwar et al. 1998; Hamanoue et al. 1999; Middleton et al. 2000). NGF in particular has been shown to increase NFB activity in various neuronal and nonneuronal populations (Wood 1995; Carter et al. 1996; Taglialatela et al. 1997; Ladiwala et al. 1998; Maggirwar et al. 1998; Yoon et al. 1998; Hamanoue et al. 1999). The present study demonstrates that NGF regulates the expression of Bcl-xL via an NFB-dependent pathway. Moreover, we demonstrate that NGF-induced NFB activation requires tyrosine phosphorylation of the inhibitor IB, but occurs independently of serine phosphorylation and degradation of IBs via the proteasome.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
were from Promega. The proteasome inhibitors carbobenzoxyl-leucinyl-leucinyl-leucinal (MG132) and lactacystin were purchased from Biomol. Sodium pervanadate (Sigma-Aldrich) was prepared as described by Imbert et al. 1996. All other chemicals came in molecular biological grade purity from Promega.
Cell Culture
Rat pheochromocytoma PC12 cells were grown in DME medium (Life Technologies) supplemented with 10% horse serum (PAN Biotech), 5% FCS (PAA) and the antibiotic mixture of 100 U/ml penicillin and 100 µg/ml streptomycin (Life Technologies). Human neuroblastoma SH-SY5Y cells were grown in RPMI 1640 medium (Life Technologies) supplemented with 10% FCS and the antibiotic mixture. Hippocampal neurons were prepared from neonatal (P1) 344 rats (Fisher Scientific) as described (Krohn et al. 1998). Cells were maintained in MEM supplemented with 10% NU®-Serum, 2% B-27 supplement (50x concentrate), 2 mM L-glutamine, 20 mM D-glucose, 26.2 mM sodium bicarbonate, and the antibiotic mixture (Life Technologies). Hippocampal neurons were plated onto poly-L-lysine–coated 35-mm Petri dishes (Becton Dickinson). Studies were performed on 8–10-d-old cultures. Animal care followed official governmental guidelines. Cultures were maintained at 37°C in a humidified atmosphere of 95% air and 5% carbon dioxide.
Reverse Transcription PCR
Total RNA was extracted using the RNeasy Mini Kit (QIAGEN). Purity of samples and RNA content were measured using a UV photometer (Amersham Pharmacia Biotech). 1 µg of total RNA was reverse-transcribed and amplified in a single reaction tube in a volume of 50 µl. The reverse transcription (RT) reaction was performed at 42°C for 20 min in the presence of oligo(dN) primers and Moloney murine leukemia virus reverse transcriptase (Amersham Pharmacia Biotech). After heat inactivation, specific oligonucleotide primer pairs for bcl-x and GAPDH (20 pmol each; MWG) were added to the reaction mixture (1.5 mM MgCl2, 60 mM KCl, 10 mM Tris-HCl, pH 9.0, 200 µM deoxynucleotides each and 2 U Taq polymerase; Amersham Pharmacia Biotech). Primer pairs were based on Mus musculus bcl-x and Rattus norvegicus GAPDH sequences. The sequences of the primers were as follows: bcl-x sense primer, 5'-GGA GAG CGT TCA GTG ATC-3' and bcl-x antisense primer, 5'-CAA TGG TGG CTG AAG AGA-3'; GAPDH sense primer, 5'-CTC GTG GTT CAC ACC CAT-3' and GAPDH antisense primer, 5'-GGC TGC CTT CTC TTG TGA-3'. PCR was performed for 22 (bcl-x) or 15 (GAPDH) cycles at 94°C for 30 s, 58°C for 60 s, and 72°C for 120 s using a Primus 25 thermocycler (MWG). The amplified PCR products (expected size for bcl-xL: 472 bp; expected size for GAPDH: 355 bp) were separated on a 5% agarose gel containing 0.1% ethidium bromide and visualized using a CCD camera-based documentation system (MWG). Intensity of bands was analyzed using ONEDscan software (Scanalytics). The intensity of the GAPDH amplification product served as internal control. Amplification temperature and cycle number with respect to the linear range of the amplification process were empirically determined for each primer pair.
SDS-PAGE and Western Blotting
Cultures were rinsed with ice-cold PBS and lysed in TBS containing SDS, glycerin, and protease inhibitors. Protein content was determined using the BCA Micro Protein Assay kit (Pierce Chemical Co.) and samples were supplemented with 2-mercaptoethanol and denaturated at 95°C for 5 min. An equal amount of protein (20–50 µg) was separated by SDS-PAGE and blotted to nitrocellulose membranes (Protean BA 85; Schleicher & Schuell). Equal loading of samples was confirmed by Ponceau red staining. Nonspecific binding was blocked at room temperature for 2 h by incubation in TBS containing 0.1% Tween-20, BSA, and nonfat dry milk. The blots were then incubated over night at 4°C with the primary antibodies diluted in blocking buffer. Antibodies used were a rabbit polyclonal anti–Bcl-x antibody (a gift from Prof. Craig B. Thompson, University of Pennsylvania, Philadelphia, PA) diluted 1:5,000, a mouse monoclonal anti–cyclooxygenase-2 (COX-2) antibody (clone 33; Transduction Laboratories) diluted 1:2,000, a rabbit polyclonal antibody specific for serine 32-phosphorylated IB (P-Ser32-IB) (New England Biolabs, Inc.) diluted 1:2,000, rabbit polyclonal antibodies recognizing IB (New England Biolabs, Inc., and sc-203; Santa Cruz Biotechnology, Inc.) diluted 1:2,000, a rabbit polyclonal antibody specific for IBβ (sc-945; Santa Cruz Biotechnology, Inc.) diluted 1:1,000, and a mouse monoclonal anti–-tubulin antibody (clone DM 1a; Sigma-Aldrich) diluted 1:2,000. Afterwards, membranes were washed and incubated with anti–mouse or –rabbit IgG-HRP conjugate (1:5,000; Promega). Antibody-conjugated peroxidase activity was visualized using the Super Signal chemiluminescence reagent (Pierce Chemical Co.). Immunoblots were stripped in stripping buffer (2% SDS, 62.5 mM Tris-HCl, 100 mM 2-mercaptoethanol, pH 6.8) for 20 min at 60°C, washed, and reprobed.
Immunocytochemistry and Visualization of the Active p65 NFB Subunit
After stimulation with NGF, cells were washed and fixed with 4% paraformaldehyde in PBS at 37°C for 20 min. Fixed cells were permeabilized by treatment with ice-cold 0.1% Triton X-100 in PBS. Nonspecific antibody binding was blocked by PBS, pH 7.4, containing 2% nonfat dry milk, 2% BSA, and 0.1% Tween 20 for 1 h at room temperature. The active p65 NFB subunit was visualized using a mouse monoclonal antibody (clone 12H11; Roche) that recognizes an epitope overlapping the nuclear location signal of the p65 NFB subunit (Zabel et al. 1993; Kaltschmidt et al. 1995). The antibody was diluted 1:100 in blocking buffer and incubated overnight at 4°C. Afterwards, cells were washed with PBS and labeled with biotin-conjugated anti–mouse IgG (1:1,000; Vector Laboratories) for 1 h at room temperature. After being washed, cells were incubated for 30 min in a mixture of avidin and biotinylated HRP reagent (Vectastain Elite ABC Kit; Vector Laboratories). Staining procedure was performed using DAB as chromogen (1 mg/ml) in the presence of Ni2+ and hydrogen peroxide. After 8–10 min, the chromogen was washed out and cells were observed in transmitted light using an Eclipse TE300 inverted microscope (Nikon). Digital images of equal exposure were acquired with a SPOT-2 camera (Diagnostic Instruments).
Analysis of NFB Reporter Gene Activity
PC12 cells were seeded on poly-L-lysine coated 24-well plates at a density of 104 cells per well. Cells were then transfected with 0.75 µg of a plasmid containing four tandem repeats of the enhancer element fused to the herpes simplex virus thymidine kinase promoter upstream of the coding sequence for a secreted form of human placental alkaline phosphatase (SEAP) (pNFB-SEAP; CLONTECH Laboratories, Inc.). In the experiment shown in Fig. 3 (below), PC12 cultures were cotransfected with 0.25 µg of a human wild-type IB expression plasmid (pIB) controlled by the cytomegalovirus promoter or control DNA of similar kilobase size. The IB expression plasmid was originally generated and published by Brockman et al. 1995. In the experiment shown in Fig. 5 (below), PC12 cells were cotransfected with 0.05 µg of a wild-type IB or mutant IB Y42F pcDNA expression plasmid (Imbert et al. 1996). In the experiments shown in Fig. 6 (below), PC12 cells were cotransfected with 0.01 or 0.05 µg of a dominant-negative TNF receptor-associated factor-6 (TRAF6 dn) expression plasmid (a gift from Dr. H. Wajant, University of Stuttgart, Stuttgart, Germany). For the generation of the dominant-negative mutant, a cDNA fragment comprising human TRAF6 (253–522) with a 5' BamHI site and a 3' NotI site was cloned into expression vector pcDNA3.1 (Invitrogen). Cells were transfected using polyethylenimine or the Lipofectamine transfection reagent (Life Technologies). 24–48 h after transfection, basal SEAP in the culture medium was washed out and fresh media containing NGF, TNF-, or vehicle was added. The medium was collected after 6 and 24 h and a fluorescence SEAP assay was performed (Great EscaAPe Fluorescence Detection Kit; CLONTECH Laboratories, Inc.) using 4-methylumbelliferyl phosphate as substrate for SEAP. Fluorescence intensity was measured using a fluorescence plate reader (HTSoft 7000; PerkinElmer) (360 nm excitation, 465 nm emission). Each set of experiments included cultures transfected with a plasmid identical to the reporter construct but lacking the enhancer element as negative control for background signals. As control for transfection efficiency, cultures were cotransfected with a pSV–β-galactosidase plasmid, and NFB reporter gene activity was normalized to β-galactosidase expression.
|
|
|
B and Immunofluorescence AnalysisB or control plasmid DNA, as well as a plasmid encoding enhanced green fluorescent protein (EGFP) as transfection control. After 72 h recovery, cells were exposed to NGF, TNF-, or vehicle for 6 h, fixed, and permeabilized as described above. After blocking for 1 h at room temperature, the specimens were incubated at 4°C overnight with the rabbit polyclonal Bcl-x antibody diluted 1:500 in blocking buffer. After washing, biotin-conjugated anti–rabbit IgG (1:1,000; Vector Laboratories) was added for 1 h at room temperature, followed by a streptavidin–Texas red conjugate (1 µg/ml, 20 min; Molecular Probes). Texas red fluorescence was observed using the Eclipse TE300 inverted microscope and a 40x oil immersion objective (Nikon) with the following optics: 510–560 nm excitation, 575 nm dichroic mirror, >590 nm emission. For the observation of the EGFP fluorescence, the following optics were used: 465–495 nm excitation, 505 nm dichroic mirror, 515–555 nm emission. Digital images of equal exposure were acquired with the SPOT-2 camera using Metamorph software (Universal Imaging Corp.). For quantification of Bcl-xL immunoreactivity, average pixel intensity of the Texas red fluorescence of single cells expressing EGFP was measured using Metamorph software. Background fluorescence intensities of the specimen were substracted from the values.
Immunoprecipitation
After exposure to NGF, sodium pervanadate, or vehicle, PC12 cells were rinsed with PBS and lysed in buffer containing (mM): 50 Tris-HCl, pH 7.5, 0.5% NP-40, 10% glycerol, 250 NaCl, 5 EDTA, 50 NaF, 0.5 Na3VO4, 10 β-glycerophosphate, and the protease inhibitors PMSF (0.5 mM), leupeptin, and aprotinin (5 µg/ml). Protein content was determined and 250 µg protein extract was immunoprecipitated using a mouse monoclonal antibody (0.5 µg) recognizing tyrosine-phosphorylated proteins (sc-508; Santa Cruz Biotechnology, Inc.). As negative control, lysates were immunoprecipitated using mouse control IgG (Santa Cruz Biotechnology, Inc.). Samples were rotated overnight at 4°C and the antibody–protein complexes were precipitated for 2 h at 4°C using protein agarose A/G plus (Santa Cruz Biotechnology, Inc.). The beads were centrifuged and washed four times. Samples were supplemented with 2-mercaptoethanol and denatured at 95°C for 2 min. Immunoprecipitated proteins were subjected to 10% SDS-PAGE, blotted, and detected using a rabbit polyclonal anti–IB antibody (sc-203; Santa Cruz Biotechnology, Inc.), diluted 1:2,000. For immunoprecipitation control, the supernatants were collected and aliquots were subjected to SDS-PAGE. IB protein was not detectable in the supernatants.
Time-Lapse Imaging of Neurons Expressing IB-EGFP
PC12 cells were plated at a density of 104 cells on 35-mm glass-bottom dishes (Willco BV) coated with poly-L-lysine. Cultures were then transfected with 0.75 µg of a plasmid encoding an IB-EGFP fusion protein (pIB-EGFP; CLONTECH Laboratories, Inc.) or a plasmid expressing EGFP. After 24-h recovery, EGFP fluorescence was observed using an Eclipse TE 300 inverted microscope and a 40x oil immersion objective equipped with the appropriate filter set (465–495 nm excitation, 505 nm dichroic mirror, 515–555 nm emission). Time-lapse digital images of equal exposure were acquired with the SPOT-2 camera using Spot software version 2.2.1. After acquiring the first image, cells transfected with pIB-EGFP were incubated with NGF, TNF-, or vehicle directly on the stage. In control experiments, cultures transfected with EGFP were exposed to TNF-. The incubation medium was enriched with 10 mM Hepes and thoroughly mixed to ensure a proper distribution of the agents. Images were analyzed using Metamorph software. Fluorescence data are given as change in average pixel intensity compared with the first image. Background fluorescence of each image was subtracted from the values.
Statistics
Data are presented as means ± SEM. For statistical comparison, one-way analysis of variance followed by LSD test were employed. Kruskal-Wallis H test followed by Bonferroni-corrected Mann-Whitney U test were used for statistical evaluation of nonparametric data. P < 0.05 was considered to be statistically significant.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
|
Nerve Growth Factor Activates NFB
NFB binding sequences have been identified in the promoter region of the human and murine bcl-x gene (Chen et al. 1999; Lee et al. 1999). To obtain evidence for increased NFB activity after treatment with NGF, we performed an immunocytochemical analysis in PC12 and SH-SY5Y cells using a monoclonal antibody raised against an epitope overlapping the nuclear localization signal of the NFB p65 subunit. This epitope is normally inaccessible because of binding of the endogenous inhibitor IB (Zabel et al. 1993; Kaltschmidt et al. 1995). Dissociation of the inhibitor exposes the nuclear localization signal of p65, enabling it to be imported into the nucleus and to activate transcription (Baeuerle and Baltimore 1988). Treatment of PC12 cells with NGF induced a strong increase in the immunoreactivity of the active NFB subunit p65 in the nucleus with maximal effects observed at a concentration of 1 ng/ml (Fig. 2, a and b). Treatment of human SH-SY5Y neuroblastoma cells with NGF also increased the immunoreactivity of the active p65 subunit, both in the cytoplasm and in the nucleus (Fig. 2c and Fig. d).
|
B activity after NGF treatment, PC12 cells were transfected with a reporter plasmid containing four tandem repeats of the enhancer element fused to the herpes simplex virus thymidine kinase promoter upstream of the coding sequence for the reporter gene SEAP. Treatment of PC12 cells with 1 ng/ml NGF induced NFB activity to an extent comparable with that induced by TNF- (10 ng/ml), a cytokine that is known to increase NFB activity in neurons (Barger et al. 1995) and that served as a positive control (Fig. 2 e). Increased NFB activity could also be detected by reporter gene analysis in human SH-SY5Y neuroblastoma cells exposed to NGF (data not shown).
Finally, evidence for increased NFB activity after NGF treatment was provided by determining the expression of the NFB target gene COX-2 (Yamamoto et al. 1995). Expression of COX-2 protein increased after treatment with NGF to a similar extent as after treatment with TNF- (Fig. 2 f).
NGF-Induced NFB Activity and Bcl-xL Expression Is Inhibited in PC12 Cells Overexpressing IB
To investigate the requirement of NFB activation for NGF-induced Bcl-xL expression, PC12 cells were transiently transfected with a plasmid encoding the NFB inhibitor IB or control DNA. Overexpression of IB reduced both NGF- and TNF-–induced NFB activity analyzed by the reporter gene assay (Fig. 3 a). We next analyzed Bcl-xL protein expression in IB-overexpressing PC12 cells cotransfected with EGFP as transfection control. In agreement with our observations described above (Fig. 1), Bcl-xL immunofluorescence increased significantly after a 6-h treatment with NGF (1 ng/ml) in cultures transfected with control DNA (Fig. 3b and Fig. c). Increased Bcl-xL expression was also observed in control-transfected PC12 cells exposed to TNF- (10 ng/ml). Overexpression of IB did not significantly alter the level of Bcl-xL expression in vehicle-treated control cells (ANOVA and LSD test; P = 0.131). Interestingly, however, NGF and TNF- failed to increase neuronal Bcl-xL expression in cells overexpressing the inhibitor.
TNF-, but Not NGF Induces Rapid Degradation of IBs
IB degradation has been shown to be required for activation of NFB by proinflammatory cytokines (Palombella et al. 1994). We therefore determined a time course of IB protein degradation in PC12 cells exposed to TNF- or NGF (Fig. 4, a and b). TNF- induced significant IB degradation, starting 10 min after the onset of treatment. In contrast, treatment with NGF for up to 8 h failed to induce significant degradation of IB. NGF also failed to trigger the degradation of a second NFB inhibitory protein, IBβ (Thompson et al. 1995). In contrast, IBβ degradation also occurred in TNF-–treated cultures, albeit with slower kinetics.
|
B degradation in response to NGF and TNF- on the single cell level, PC12 cells were transfected with a plasmid encoding EGFP-tagged IB. The fusion protein has been previously shown to be degraded after serine phosphorylation with kinetics similar to IB, resulting in a decrease in cellular IB-EGFP fluorescence (Li et al. 1999). Treatment of IB-EGFP–transfected cells with TNF- induced a significant decrease in fluorescence after 10 min of exposure (Fig. 4 c). In contrast, cellular IB-EGFP fluorescence did not decrease in cells treated with NGF or vehicle monitored up to 2 h. As a control for specificity of the TNF- induced decrease in IB-EGFP fluorescence, PC12 cells were transfected with a plasmid encoding EGFP. Treatment with TNF- did not induce a decrease in cellular EGFP fluorescence.
IB Is Not Phosphorylated at Serine 32 after NGF Stimulation
IB has been shown to be phosphorylated at serine 32 and 36 residues after treatment with NFB-inducing cytokines (Brown et al. 1995; Traenckner et al. 1995). To investigate serine phosphorylation of IB after treatment with NGF, we performed immunoblot experiments using an antibody specific for P-Ser32-IB. While treatment of PC12 cells with TNF- induced an increase in P-Ser32-IB after 10 min of exposure with maximal effects seen after 30 min, NGF failed to induce any significant increase in P-Ser32-IB up to 8 h after its addition to the cultures (Fig. 5 a). At this time point, NGF had already caused a pronounced increase in NFB activity (Fig. 2). The (lack of) effect was independent of the NGF concentration used, as similar results were obtained in cultures treated with 10 ng/ml NGF (data not shown). TNF-–, but not NGF-induced serine 32 phosphorylation of IB was also observed in human SH-SY5Y neuroblastoma cells (Fig. 5 b).
Tyrosine Phosphorylation of IB in NGF-stimulated PC12 Cells
Phosphorylation of IB at tyrosine residue 42 has been shown to activate NFB without requiring IB degradation via the proteasome (Imbert et al. 1996; Béraud et al. 1999). We performed immunoprecipitation experiments to analyze tyrosine phosphorylation of IB. PC12 cells were exposed to NGF (10 ng/ml) or sodium pervanadate (200 µM) as a positive control, and cytosolic extracts were subjected to immunoprecipitation using a murine monoclonal antibody raised against tyrosine-phosphorylated proteins. As a negative control, cell lysates were immunoprecipitated with mouse control IgG. Detection of immunoprecipitated proteins by SDS-PAGE and Western blot analysis using an IB antibody demonstrated that sodium pervanadate induced significant tyrosine phosphorylation of IB (Fig. 5 c). Treatment with NGF also induced strong tyrosine phosphorylation of IB after 120 min of treatment. Tyrosine-phosphorylated IB could also be detected in response to TNF- (data not shown), presumably a consequence of the known ability of NFB-activating cytokines to stimulate NGF synthesis in neural cells (Hattori et al. 1993; Friedman et al. 1996).
To investigate whether phosphorylation of IB at tyrosine residue 42 mediated NGF-induced NFB activation, cells were transfected with a plasmid encoding wild-type IB or a mutant IB (Y42F), which has been shown to block NFB activation after tyrosine phosphorylation of IB (Imbert et al. 1996). We titrated down the amount of wild-type IB plasmid DNA to a concentration at which NGF and TNF- were still able to elicit significant NFB activation (Fig. 5 d). Transfection with the same concentration of plasmid DNA encoding mutant Y42F IB led to a complete inhibition of NGF-induced NFB activation. In contrast, TNF-–induced NFB activation was not inhibited by the IB Y42F mutant.
Overexpression of a Dominant-Negative Mutant of TRAF-6 Inhibits TNF--, but Not NGF-induced NFB Activation
TRAF proteins are proximal signaling components required for TNF-–induced NFB activation (Rothe et al. 1995). In a similar pathway, selective activation of NFB via p75 NGF receptors has been shown to involve the association of TRAF6 to the receptor complex (Khursigara et al. 1999; Ye et al. 1999; Foehr et al. 2000). To demonstrate differential activation pathways for TNF- and NGF upstream of IB phosphorylation, we transiently expressed TRAF6 dn in PC12 cells (Fig. 6). Overexpression of TRAF6 dn potently inhibited TNF-–, but failed to inhibit NGF-induced NFB activation.
NGF Induces Bcl-xL Expression in the Presence of Proteasome Inhibitors
NFB activation via tyrosine phosphorylation of IB occurs independently of IB ubiquitination and degradation via the proteasome (Imbert et al. 1996; Béraud et al. 1999). To demonstrate that NGF was able to induce the expression of NFB-target genes independent of the proteasome, we treated PC12 cells with two proteasome inhibitors, MG132 and lactacystin. Treatment with these inhibitors significantly reduced basal Bcl-xL expression in PC12 cells (Fig. 7 a). As expected, treatment with NGF was able to induce a strong increase in Bcl-xL expression in the presence of the two inhibitors. Semiquantitative RT-PCR revealed that NGF also increased neuronal bcl-xL mRNA expression in cultures treated with proteasome inhibitors (data not shown). Similarly, NGF increased the expression of the NFB target gene COX-2 in the presence of the proteasome inhibitor lactacystin (Fig. 7 b). In contrast, treatment with lactacystin inhibited TNF-–induced Bcl-xL expression (Fig. 7 c).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
B inhibitor IB, indicating that NFB activation was required for the upregulation of neuronal Bcl-xL expression (Tamatani et al. 1999; Foehr et al. 2000). NGF also increases the expression of Bcl-2 (Riccio et al. 1999), an antiapoptotic protein closely related to Bcl-xL. Interestingly, upregulation of Bcl-2 by NGF involves a CREB-dependent transcriptional pathway (Liu et al. 1999; Riccio et al. 1999). It is remarkable that NGF has the capacity to increase the neuronal expression of two antiapoptotic proteins with a similar mechanism of action, via two separate transcriptional pathways. Activation of NFB has also been shown to increase the expression of inhibitor of apoptosis proteins (You et al. 1997; Stehlik et al. 1998). These proteins have been identified as NGF-inducible target genes in chicken (Wiese et al. 1999), and function as endogenous inhibitors of a family of proapoptotic cysteine proteases, the caspases. It is therefore conceivable that the survival-promoting effects of NGF are largely mediated via an increased transcription of genes that are conserved components of the apoptotic cell death machinery.
TNFs- and -β, as well as cytokines of the interleukin-6 family have also been shown to increase NFB activity in cultured neurons (Barger et al. 1995; Middleton et al. 2000). In the present study, treatment with NGF induced a significant NFB activity comparable with that induced by TNF-. Of note, our data demonstrate that the pathway activated by NGF is distinct from that activated by TNF-. NFB activity induced by TNF- involves serine phosphorylation of IB proteins via IB kinases (DiDonato et al. 1997; Malinin et al. 1997; Mercurio et al. 1997), resulting in the subsequent ubiquitination and degradation by the proteasome. Both events, serine phosphorylation of IB and degradation of IB proteins, could be clearly detected in response to TNF-. In contrast, NGF did not lead to significant serine phosphorylation, but instead induced tyrosine phosphorylation of IB. The effect of NGF was mimicked by pervanadate, an agent that activates NF-B via tyrosine phosphorylation of IB at residue 42 (Imbert et al. 1996; Singh et al. 1996). Importantly, overexpression of a Y42F mutant of IB potently suppressed NFG-, but not TNF-–induced NFB activation. This suggests that (a) tyrosine phosphorylation at this site is required for NGF-induced NFB activation, and (b) TNF-–induced serine phosphorylation of IB is sufficient to activate NFB.
Phosphorylation of IB on tyrosine residue 42 has also been observed pathophysiologically in response to hypoxia/reoxygenation (Koong et al. 1994). However, our report is the first demonstration of ligand-induced tyrosine phosphorylation of IB. Tyrosine-phosphorylated IB has been reported to have a half life similar to that of nonphosphorylated IB, and activation of NFB may occur by a degradation-independent dissociation of the inhibitor from the p65 subunit (Imbert et al. 1996; Béraud et al. 1999). Cultures treated with NGF indeed failed to provide strong evidence for IB degradation. We cannot fully exclude the absence of IB degradation in light of the rapid turnover of IB in cultured neurons and the fact that IB is rapidly resynthesized as a consequence of NFB activation (Maggirwar et al. 1998). Interestingly, however, NGF induced Bcl-xL expression in the presence of proteasome inhibitors, suggesting that serine phosphorylation, ubiquitination, and degradation via the proteasome were in fact not involved in NGF-induced NFB activation. NGF activates the PI3-kinase/Akt kinase pathway in neurons (Yao and Cooper 1995; Crowder and Freeman 1998; Xue et al. 2000). Béraud et al. 1999 have recently demonstrated that both the regulatory p85 and the catalytic p110 subunit of PI3-kinase are involved in NFB activation after tyrosine phosphorylation of IB. The authors observed an interaction of the COOH-terminal SH2 domain of p85 with tyrosine phosphorylated IB. It remains to be shown whether this interaction induces a dissociation of the IB/NFB complex in the absence of IB degradation. However, NGF-induced PI3-kinase/Akt activation may also stimulate additional regulatory steps in NFB-dependent gene transcription; for example, by increasing the transactivation potential of NFB (Madrid et al. 2000).
The rat pheochromocytoma PC12 and the human neuroblastoma SH-SY5Y cells used in the present study express both the trkA and p75 neurotrophin receptors (our unpublished data). Submaximal NGF concentrations (0.1–1 ng/ml) were sufficient to induce NFB activity and Bcl-xL expression, suggesting that the p75 receptor may play a role in potentiating the effect of NGF transduced via the trkA receptor (Davies et al. 1993). Interestingly, the p75 receptor has also been shown to signal NGF-induced NF-B activity in the absence of trkA receptors (Carter et al. 1996; Ladiwala et al. 1998; Yoon et al. 1998). Moreover, NGF-induced NFB activation via selective activation of p75 in the trkA-deficient Schwann cell line RN22 has been shown to involve both serine phosphorylation and degradation of IB (Gentry et al. 2000). It is conceivable that, in the absence of trkA, NGF activates NF-B via a pathway resembling that induced by TNF-. In support of this concept, the p75 receptor also associates with TRAF proteins (Khursigara et al. 1999; Ye et al. 1999), adaptor proteins that are required for TNF-–induced NFB activation (Rothe et al. 1995). In the present study, TNF-–induced NFB activation in PC12 cells was potently inhibited by overexpression of a dominant-negative mutant of TRAF6, while NGF-induced NFB activation was not suppressed. Because selective activation of NFB via p75 NGF receptors has been shown to be sensitive to overexpression of dominant-negative TRAF6 (Khursigara et al. 1999; Foehr et al. 2000), NGF-induced NFB activation in PC12 cells primarily involved a signal transduction pathway downstream of trkA receptors. Nevertheless, the extent of serine and tyrosine phosphorylation of IBs as well as the extent of IB degradation via the proteasome in response to NGF may vary in different cell types depending on the relative contribution of the signal transduction pathways activated by p75 and trkA receptors (Hamanoue et al. 1999).
There is also evidence for a cross talk between Akt and IB kinase activation (Ozes et al. 1999; Romashkova and Makarov 1999; Foehr et al. 2000), although this is discussed controversially in the literature (Béraud et al. 1999; Madge and Pober 2000; Rauch et al. 2000). As serine phosphorylation of IB and degradation of IBs and β were not detected in PC12 and SH-SY5Y cells in response to NGF, it is conceivable that activation of IB kinases via Akt kinase or the Raf/ERK kinase pathway (Nakano et al. 1998; Nemoto et al. 1998) contributed little to NGF-induced NF-B activation in our study. Interestingly, it has recently been demonstrated that the Raf/ERK pathway negatively regulates NFB-dependent gene expression in cultured fibroblasts (Carter and Hunninghake 2000), a potential mechanism for the decline in Bcl-xL expression in cultures treated with higher NGF concentrations.
In summary, our study demonstrates that NGF-induced NFB activity and Bcl-xL expression require tyrosine phosphorylation of IB. Activation of NFB via different ligand-receptor systems and downstream signal transduction pathways may enable the nervous system to maintain constitutive NFB activity while responding with an increased NFB activity during injury, inflammation, or repair processes. Moreover, the nonredundancy of NFB activation pathways emphasizes the importance of this transcription factor for neuronal survival.
|
Acknowledgments |
|---|
B, and Dr. H. Wajant for plasmid pTRAF6 dn. This work was supported by the Deutsche Forschungsgemeinschaft (Pr 338/8-1).
Submitted: 8 September 2000
Revised: 4 January 2001
Accepted: 12 January 2001
Abbreviations used in this paper: COX-2, cyclooxygenase-2; EGFP, enhanced green fluorescent protein; NF
B, nuclear factor-B; P-Ser32-IB, serine 32-phosphorylated IB; RT, reverse transcription; SEAP, secreted form of human placental alkaline phosphatase; TNF-, tumor necrosis factor-; TRAF6 dn, dominant negative tumor necrosis factor receptor-associated factor-6.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Baeuerle P.A. & Baltimore D.. IBa specific inhibitor of the NF-B transcription factor, Science., 242, 1988, 540–546.
Barger S.W., Hörster D., Furukawa K., Goodman Y., Krieglstein J. & Mattson M.P.. Tumor necrosis factors alpha and beta protect neurons against amyloid beta-toxicityevidence for involvement of a kappa B–binding factor and attenuation of peroxide and Ca2+ accumulation, Proc. Natl. Acad. Sci. USA., 92, 1995, 9328–9332.
Béraud C., Henzel W.J. & Baeuerle P.. Involvement of regulatory and catalytic subunits of phosphoinositide 3-kinase in NFB activation, Proc. Natl. Acad. Sci. USA., 96, 1999, 429–434.
Boise L.H., Gonzalez-Garcia M., Postema C.E., Ding L., Lindsten L.A., Turka L.A., Mao X., Nuñez G. & Thompson C.B.. Bcl-x, a bcl-2–related gene that functions as a dominant regulator of apoptotic death, Cell., 74, 1993, 597–608.[Medline]
Brockman J.A., Scherer D.C., McKinsey T.A., Hall S.M., Qi X., Lee W.Y. & Ballard D.W.. Coupling of a signal response domain in IB to multiple pathways for NF-B activation, Mol. Cell. Biol., 15, 1995, 2809–2818.
Brown K., Gerstberger S., Carlson L., Franzoso G. & Siebenlist U.. Control of IB- proteolysis by site-specific, signal-induced phosphorylation, Science., 267, 1995, 1485–1488.
Carter A.B. & Hunninghake G.W.. A constitutive active MEK
ERK pathway negatively regulates NF-B–dependent gene expression by modulating TATA binding protein phosphorylation, J. Biol. Chem., 275, 2000, 27858–27864.
Carter B.D., Kaltschmidt C., Kaltschmidt B., Offenhäuser N., Böhm-Mathaei R., Baeuerle P.A. & Barde Y.A.. Selective activation of NF-B by nerve growth factor through the neurotrophin receptor p75, Science., 272, 1996, 542–545.[Abstract]
Chen C., Edelstein L.C. & Gélinas C.. The Rel/NFB family directly activates expression of the apoptosis inhibitor Bcl-xL, Mol. Cell. Biol., 20, 2000, 2687–2695.
Chen F., Demers L.M., Vallayathan C., Yongju L., Castranova V. & Shi X.. Involvement of 5'-flanking B-like sites within bcl-x gene in silica-induced Bcl-x expression, J. Biol. Chem., 274, 1999, 35591–35595.
Crowder R.J. & Freeman R.S.. Phosphatidylinositol 3-kinase and Akt protein kinase are necessary and sufficient for the survival of nerve growth factor-dependent sympathetic neurons, J. Neurosci., 18, 1998, 2933–2943.
Davies A.M., Lee K.F. & Jaenisch R.. p75-Deficient trigeminal sensory neurons have an altered response to NGF but not to other neurotrophins, Neuron., 2, 1993, 1275–1284.
DiDonato J.A., Hayakawa M., Rothwarf D.M., Zandi E. & Karin M.. A cytokine-responsive IB kinase that activates the transcription factor NF-B, Nature., 388, 1997, 853–862.
Dumon S., Rosa Santos S.C., Debierre-Grockiego F., Gouilleux-Gruart V., Cocault L., Boucheron C., Mollat P., Gisselbrecht S. & Gouilleux F.. IL-3 dependent regulation of Bcl-xL gene expression by STAT5 in a bone marrow derived cell line, Oncogene., 18, 1999, 4191–4199.[Medline]
Foehr E.D., Lin X., O'Mahony A., Geleziunas R., Bradshaw R.A. & Greene W.C.. NF-B signaling promotes both cell survival and neurite process formation in nerve growth factor-stimulated PC12 cells, J. Neurosci., 20, 2000, 7556–7563.
Friedman W.J., Thakur S., Seidman L. & Rabson A.B.. Regulation of nerve growth factor mRNA by interleukin-1 in rat hippocampal astrocytes is mediated by NFB, J. Biol. Chem., 271, 1996, 31115–31120.
Gentry J.J., Casaccia-Bonnefil P. & Carter B.D.. Nerve growth factor activation of nuclear factor-B through its p75 receptor is an anti–apoptotic signal in RN22 Schwannoma cells, J. Biol. Chem., 275, 2000, 7558–7565.
Gonzalez-Garcia M., Garcia I., Ging L.Y., Oshea S., Boise L.H., Thompson C.B. & Nuñez G.. Bcl-x is expressed in embryonic and postnatal neural tissue and functions to prevent neuronal cell death, Proc. Natl. Acad. Sci. USA., 92, 1995, 4304–4308.
Hamanoue M., Middleton G., Wyatt S., Jaffray E., Hay R.T. & Davies A.M.. p75-Mediated NFB activation enhances the survival response of developing sensory neurons to nerve growth factor, Mol. Cell. Neurosci., 14, 1999, 28–40.[Medline]
Hattori A., Tanaka E., Murase K., Ishida N., Chatani Y., Tsujimoto M., Hayashi K. & Kohno M.. Tumor necrosis factor stimulates the synthesis and secretion of biologically active nerve growth factor in non-neuronal cells, J. Biol. Chem., 268, 1993, 2577–2582.
Imbert V., Rupec R.A., Livolsi A., Pahl H.L., Traenckner E.B.M., Mueller-Dieckmann C., Farahifar D., Rossi B., Auberger P., Baeuerle P.A. & Peyron J.F.. Tyrosine phosphorylation of IB- activates NFB without proteolytic degradation of IB-, Cell., 86, 1996, 787–798.[Medline]
Kaltschmidt C., Kaltschmidt B. & Baeuerle P.A.. Stimulation of ionotropic glutamate receptors activates transcription factor NF-kappaB in primary neurons, Proc. Natl. Acad. Sci. USA, 92, 1995, 9618–9622.
Khursigara G., Orlinick J.R. & Chao M.V.. Association of the p75 neurotrophin receptor with TRAF6, J. Biol. Chem., 274, 1999, 2597–2600.
Koong A.C., Chen E.Y. & Giacca A.J.. Hypoxia causes the activation of nuclear factor B through the phosphorylation of IB on tyrosine residues, Cancer Res., 54, 1994, 1425–1430.
Krohn A.J., Preis E. & Prehn J.H.M.. Staurosporine-induced apoptosis of cultured rat hippocampal neurons involves caspase-1–like proteases as upstream initiators and increased production of superoxide as a main downstream effector, J. Neurosci., 18, 1998, 8186–8197.
Ladiwala U., Lachance C., Simoneau S.J.J., Bhakar A., Barker P.A. & Antel J.P.. p75 Neurotrophin receptor expression on adult human oligodendrocytessignaling without cell death in response to NGF, J. Neurosci., 18, 1998, 1297–1304.
Lee H.H., Dadgostar H., Cheng Q., Shu J. & Cheng G.. NF-B–mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes, Proc. Natl. Acad. Sci. USA., 96, 1999, 9136–9141.
Li X., Fang Y., Zhao X., Jiang X., Duong T. & Kain S.R.. Characterization of NF-B activation by detection of green fluorescent protein–tagged IB degradation in living cells, J. Biol. Chem., 274, 1999, 21244–21250.
Liu Y.Z., Boxer L.M. & Latchman D.S.. Activation of the Bcl-2 promoter by nerve growth factor is mediated by the p42/p44 MAPK cascade, Nucleic Acids Res., 27, 1999, 2086–2090.
Madge L.A. & Pober J.S.. A phosphatidylinositol 3-kinase/Akt pathway, activated by tumor necrosis factor or interleukin-1, inhibits apoptosis but does not activate NFB in human endothelial cells, J. Biol. Chem., 275, 2000, 15458–15465.
Madrid L.V., Wang C.Y., Guttridge D.C., Schottelius A.J.G., Baldwin A.S. Jr. & Mayo M.W.. Akt suppresses apoptosis by stimulating the transactivation potential of the RelA/p65 subunit of NF-B, Mol. Cell. Biol., 20, 2000, 1626–1638.
Maggirwar S.B., Sarmiere P.D., Dewhurst S. & Freeman R.S.. Nerve growth factor–dependent activation of NF-B contributes to survival of sympathetic neurons, J. Neurosci, 18, 1998, 10356–10365.
Malinin N.L., Boldin M.P., Kovalenko A.V. & Wallach D.. MAP3K-related kinase involved in NF-B induction by TNF, CD95 and IL-1, Nature., 385, 1997, 540–544.[Medline]
Mercurio F., Zhu H., Murray B.W., Shevchenko A., Bennet B.L., Li J., Young D., Barbosa M., Mann M., Manning A.M. & Rao A.. IKK-1 and IKK-2cytokine-activated IB kinase essential for NF-B activation, Science., 278, 1997, 860–866.
Middleton G., Hamanoue M., Enokido Y., Wyatt S., Pennica D., Jaffray E., Hay R.T. & Davies A.M.. Cytokine-induced nuclear factor kappa B activation promotes the survival of developing neurons, J. Cell Biol., 148, 2000, 325–332.
Motoyama N., Wang F., Roth K.A., Sawa H., Nakayama K., Negishi I., Senju S., Zhang Q., Fujii S. & Loh D.. Massive cell death of immature hematopoietic cells and neurones in Bcl-x–deficient mice, Science., 267, 1995, 1506–1510.
Nakano H., Shindo M., Sakon S., Nishinaka S., Mihara M., Yagita H. & Okumara K.. Differential regulation of IB kinase and β by two upstream kinases, NF-B–inducing kinase and mitogen-activated protein kinase/ERK kinase kinase-1, Proc. Natl. Acad. Sci. USA., 95, 1998, 3537–3542.
Nemoto S., DiDonato J.A. & Lin A.. Coordinate regulation of IB kinases by mitogen-activated protein kinase kinase 1 and NF-B–inducing kinase, Mol. Cell. Biol., 18, 1998, 7336–7343.
Ozes O.N., Mayo L.D., Gustin J.A., Pfeffer S.R., Pfeffer L.M. & Donner D.B.. NF-B activation by tumour necrosis factor requires the Akt serine-threonine kinase, Nature., 401, 1999, 82–85.[Medline]
Palombella V., Rando O., Goldberg A. & Maniatis T.. The ubiquitin-proteasome pathway is required for processing the NFB1 precursor protein and the activation of NF-B, Cell., 78, 1994, 773–785.[Medline]
Parsadanian A.S., Cheng Y., Keller-Peck C.R., Holtzman D.M. & Snider W.D.. Bcl-xL is an antiapoptotic regulator for postnatal CNS neurons, J. Neurosci., 18, 1998, 1009–1019.
Prehn J.H.M., Bindokas V.P., Marcuccilli C.J., Krajewski S., Reed J.C. & Miller R.J.. Regulation of neuronal Bcl2 protein expression and calcium homeostasis by transforming growth factor type β confers wide-ranging protection on rat hippocampal neurons, Proc. Natl. Acad. Sci. USA., 91, 1994, 12599–12603.
Prehn J.H.M, Bindokas V.P., Jordan J., Galindo M.F., Roos R.P., Ghadge G.D., Boise L.H., Thompson C.B., Krajewski S., Reed J.C. & Miller R.J.. Protective effects of transforming growth factor-β1 (TGF-β1) on β-amyloid neurotoxicity in rat hippocampal neurons, Mol. Pharmacol., 49, 1996, 319–328.[Abstract]
Rauch B.H., Weber A., Braun M., Zimmermann N. & Schrör K.. PDGF-induced Akt phosphorylation does not activate NF-B in human vascular smooth muscle cells and fibroblasts, FEBS Lett., 481, 2000, 3–7.[Medline]
Riccio A., Ahn S., Davenport C.M., Blendy J.A. & Ginty D.D.. Mediation by a CREB family transcription factor of NGF-dependent survival of sympathetic neurons, Science., 286, 1999, 2358–2361.
Romashkova J.A. & Makarov S.S.. NF-B is a target of Akt in anti-apoptotic PDGF signalling, Nature., 401, 1999, 86–90.[Medline]
Rong P., Bennie A.M., Epa W.R. & Barrett G.L.. Nerve growth factor determines survival and death of PC12 cells by regulation of the bcl-x, bax, and caspase-3 genes, J. Neurochem., 72, 1999, 2294–2300.[Medline]
Rothe M., Sarma V., Dixit V.M. & Goeddel D.V.. TRAF2-mediated activation of NK-B by TNF receptor 2 and CD40, Science., 269, 1995, 1424–1427.
Singh S., Darnay B.G. & Aggarwal B.B.. Site-specific tyrosine phosphorylation of IB negatively regulates its inducible phosphorylation and degradation, J. Biol. Chem., 271, 1996, 31049–31054.
Socolovsky M., Fallon A.E.J, Wang S., Brugnara C. & Lodish H.F.. Fetal anemia and apoptosis of red cell progenitors in Stat5a–/–5b–/– micea direct role for Stat5 in Bcl-xL induction, Cell., 98, 1999, 181–191.[Medline]
Stehlik C., de Martin R., Kumbashiri I., Schmid J.A., Binder B.R. & Lipp J.. Nuclear factor (NF)-B–regulated X-chromosome–linked iap gene expression protects endothelial cells from tumor necrosis factor -induced apoptosis, J. Exp. Med., 188, 1998, 211–216.
Taglialatela G., Robinson R. & Perez-Polo J.R.. Inhibition of nuclear factor kappa B (NFB) activity induces nerve growth factor-resistant apoptosis in PC12 cells, J. Neurosci. Res., 47, 1997, 155–162.[Medline]
Tamatani M., Che Y.H., Matsuzaki H., Ogawa S., Okado H., Miyake S.I., Mizuno T. & Tohyama M.. Tumor necrosis factor induces Bcl-2 and Bcl-xL expression through NFB activation in primary hippocampal neurons, J. Biol. Chem., 274, 1999, 8531–8538.
Thompson J.E., Phillips R.J., Erdjument-Bromage H., Tempst P. & Ghosh S.. IB-β regulates the persistent response in a biphasic activation of NF-B, Cell., 80, 1995, 573–582.[Medline]
Traenckner E.B., Pahl H.L., Henkel T., Schmidt K.N., Wilk S. & Baeuerle P.A.. Phosphorylation of human IB- on serines 32 and 36 controls IB- proteolysis and NF-B activation in response to diverse stimuli, EMBO (Eur. Mol. Biol. Organ.) J., 14, 1995, 2876–2883.[Medline]
Wiese S., Digby M.R., Gunnersen J.M., Götz R., Pei G., Holtmann B., Lowenthal J. & Sendtner M.. The anti-apoptotic protein ITA is essential for NGF-mediated survival of embryonic chick neurons, Nat. Neurosci., 2, 1999, 978–983.[Medline]
Wiessner C., Allegrini P.R., Rupalla K., Sauer D., Oltersdorf T., McGregor A.L., Bischoff S., Bottinger B.W. & van der Putten H.. Neuron-specific transgene expression of Bcl-xL but not Bcl-2 genes reduced lesion size after permanent middle cerebral artery occlusion in mice, Neurosci. Lett., 268, 1999, 119–122.[Medline]
Wood J.N.. Regulation of NFB activity in rat dorsal root ganglia and PC12 cells by tumour necrosis factor and nerve growth factor, Neurosci. Lett., 192, 1995, 41–44.[Medline]
Xue L., Murray J.H. & Tolkovsky A.M.. The Ras/phosphatidylinositol 3-kinase and Ras/ERK pathways function as independent survival modules each of which inhibits a distinct apoptotic signaling pathway in sympathetic neurons, J. Biol. Chem., 275, 2000, 8817–8824.
Yamamoto K., Arakawa T., Ueda N. & Yamamoto S.. Transcriptional roles of nuclear factor kappa B and nuclear factor–interleukin-6 in the tumor necrosis factor–-dependent induction of cyclooxygenase-2 in MC3T3-E1 cells, J. Biol. Chem., 270, 1995, 31315–31320.
Yao R. & Cooper G.M.. Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor, Science., 267, 1995, 2003–2006.
Ye X., Mehlen P., Rabizadeh S., VanArsdale T., Zhang H., Shin H., Wang J.J.L., Leo E., Zapata J. & Hauser C.A.. TRAF family proteins interact with the common neurotrophin receptor and modulate apoptosis induction, J. Biol. Chem., 274, 1999, 30202–30208.
Yoon S.O., Casaccia-Bonnefil P., Carter B. & Chao M.V.. Competitive signaling between TrkA and p75 nerve growth factor receptor determines cell survival, J. Neurosci., 18, 1998, 3273–3281.
You M., Ku P.T., Hrdlicková R. & Bose H.R. Jr.. ch-IAP1, a member of the inhibitor-of-apoptosis protein family, is a mediator of the antiapoptotic activity of the v-Rel oncoprotein, Mol. Cell. Biol., 17, 1997, 7328–7341.
Zabel U., Henkel T., Silva M.S. & Baeuerle P.A.. Nuclear uptake control of NF-B by MAD-3, an IB protein present in the nucleus, EMBO (Eur. Mol. Biol. Organ.) J., 12, 1993, 201–211.[Medline]
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
